Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
复制标题
DOI：
10.6004/jnccn.2015.0167
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
National Comprehensive Cancer Network
中科院分区：
文献类型：
--
作者：
Anderson KC;Alsina M;Atanackovic D;Biermann JS;Chandler JC;Costello C;Djulbegovic B;Fung HC;Gasparetto C;Godby K;Hofmeister C;Holmberg L;Holstein S;Huff CA;Kassim A;Krishnan AY;Kumar SK;Liedtke M;Lunning M;Raje N;Singhal S;Smith C;Somlo G;Stockerl-Goldstein K;Treon SP;Weber D;Yahalom J;Shead DA;Kumar R;National Comprehensive Cancer Network
多发性骨髓瘤(MM)是一种浆细胞的恶性肿瘤，积聚在骨髓中，导致骨破坏和骨髓衰竭。美国癌症协会最近的统计数据表明，多发性骨髓瘤的发病率正在增加。本期收录的NCCN肿瘤学临床实践指南(NCCN指南)涉及孤立性浆细胞瘤患者和新诊断的MM的管理。
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) included in this issue address management of patients with solitary plasmacytoma and newly diagnosed MM.